Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):472-9. doi: 10.1097/QAI.0b013e3181cae480.
To assess the effect of pol replication capacity (RC) on the hazard ratio of progression to a composite endpoint of time to progression to <350 CD4+ cells per microliter, initiation of therapy, or death.
pol RC assays were performed after study closure in baseline samples obtained from 316 enrollees in a prospectively monitored cohort of treatment-naive adults with >or=450 CD4+ cells per microliter and >or=1000 HIV-1 RNA copies per milliliter.
The median RC was 79%. Patients with a lower RC had a lower median viral load (4.0 vs 4.2 Log HIV-1 RNA copies/mL, P = 0.026) and a lower rate of protease inhibitor resistance 2% vs 8%, P = 0.03). Otherwise, baseline demographic and laboratory characteristics were similar. The hazard ratio of progression to the composite endpoint was 0.73 (P = 0.041) for persons with lower RC, 2.07 per 1.0 log10 higher viral load (P < 0.001), and 0.86 per 50 cells per microliter higher CD4+ cell count (P < 0.001). The effect of lower RC was also significant in a separate analysis of time to initiation of therapy (P = 0.04).
These results show that untreated patients with lower vs higher RC had a slower rate of progression as assessed by a composite outcome of time to CD4+ count <or=350 cells per microliter, treatment initiation, or death.
评估聚合酶复制能力(RC)对复合终点进展风险比的影响,该终点包括从进展至每微升<350 个 CD4+细胞、开始治疗或死亡的时间、进展至该终点的时间、开始治疗或死亡。
在一项前瞻性监测的、未经治疗的成人队列研究中,在基线时获得了 316 名患者的样本,这些患者的 CD4+细胞计数>450 个/微升,HIV-1 RNA 拷贝数>1000 个/ml,研究结束后进行了 pol RC 检测。
中位 RC 为 79%。RC 较低的患者病毒载量中位数较低(4.0 对 4.2 Log HIV-1 RNA 拷贝/ml,P = 0.026),蛋白酶抑制剂耐药率较低(2%对 8%,P = 0.03)。其他基线人口统计学和实验室特征相似。RC 较低的患者进展为复合终点的风险比为 0.73(P = 0.041),每增加 1.0 log10 病毒载量,风险比为 2.07(P < 0.001),每增加 50 个细胞/微升 CD4+细胞计数,风险比为 0.86(P < 0.001)。在对开始治疗时间的单独分析中,低 RC 的效果也很显著(P = 0.04)。
这些结果表明,未经治疗的患者中,RC 较低的患者与 RC 较高的患者相比,复合终点(进展至每微升<350 个 CD4+细胞、开始治疗或死亡的时间)的进展速度较慢。